Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Bayer (BAYRY - Analyst Report) received favorable news from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) when it provided a positive opinion on the approval of radium Ra 223 dichloride (radium-223) last week.

Bayer is looking to get radium-223 approved for treating adults suffering from castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases.

A final verdict from the European Commission on the approval of radium-223 is expected by year end. We note that though the European Commission is not bound to follow the CHMP’s decision, it generally does so.

The positive CHMP recommendation on the approval of radium-223 was based on positive results from the phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study. Results from the study revealed that treatment with radium-223 resulted in a significant improvement in overall survival and also caused a reduction in the risk of death compared to patients in the placebo arm.

We remind investors that the U.S. Food and Drug Administration (FDA) approved the drug in May 2013 for the above indications, based on the positive results from the ALSYMPCA study. Following the approval, the drug is marketed in the U.S. under the trade name Xofigo. Xofigo is co-promoted by Bayer and Algeta U.S., LLC in the U.S. as per a 2009 agreement. Bayer however has the rights to commercialize the product worldwide.

We are encouraged by Bayer’s progress on radium-223. However, the prostate cancer market looks extremely crowded with the presence of companies like Johnson & Johnson (JNJ - Analyst Report) and Medivation Inc. (MDVN - Analyst Report).

Bayer, a large-cap pharma company, presently carries a Zacks Rank #2 (Buy). Roche (RHHBY - Analyst Report) looks more attractive in the large-cap space with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%